UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended March 31, 2019

o   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 000-27163

 

SWK Holdings Corporation

(Exact Name of Registrant as Specified in its Charter)

Delaware	77-0435679
(State or Other Jurisdiction of Incorporation   or Organization)	(I.R.S. Employer Identification No.)
14755 Preston Road, Suite 105   Dallas, TX	75254 (Zip Code)
(Address of Principal Executive Offices)

(Registrant’s Telephone Number, Including Area Code): (972) 687-7250

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  x  YES  o  NO

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). x  YES  o  NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large Accelerated Filer   o   Accelerated Filer   o   Non-Accelerated Filer   o   Smaller Reporting Company    x    Emerging Growth Company   o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  o  YES  x  NO

As of May 9, 2019, there were 12,897,646 shares of the registrant’s Common Stock, $0.001 par value per share, outstanding.

SWK Holdings Corporation

Form 10-Q

Quarter Ended March 31, 2019

Table of Contents

PART I. FINANCIAL INFORMATION
Item 1.	Financial Statements	1
	Unaudited Condensed Consolidated Balance Sheets—March 31, 2019 and December 31, 2018	1
	Unaudited Condensed Consolidated Statements of Income—Three Months Ended March 31, 2019 and 2018	2
	Unaudited Condensed Consolidated Statements of Comprehensive Income—Three Months Ended March 31, 2019 and 2018	3
	Unaudited Condensed Consolidated Statements of Stockholders’ Equity—Three Months Ended March 31, 2019 and 2018	4
	Unaudited Condensed Consolidated Statements of Cash Flows—Three Months Ended March 31, 2019 and 2018	5
	Notes to the Unaudited Condensed Consolidated Financial Statements	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	23
Item 4.	Controls and Procedures	23
PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	24
Item 1A.	Risk Factors	24
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	24
Item 3.	Defaults Upon Senior Securities	24
Item 4.	Mine Safety Disclosures	24
Item 5.	Other Information	24
Item 6.	Exhibits	25
	Signatures	26
	Certifications

FORWARD-LOOKING STATEMENTS

In addition to historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. From time to time, we may also provide oral or written forward-looking statements in other materials we release to the public. Such forward-looking statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. The forward-looking statements are not historical facts but rather are based on current expectations, estimates and projections about our business and industry, and our beliefs and assumptions, and include, but are not limited to, statements under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Words such as “anticipate,” “believe,” “estimate,” “expects,” “intend,” “plan,” “will” and variations of these words and similar expressions identify forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, many of which are beyond our control, are difficult to predict and could cause actual results to differ materially (both favorably and unfavorably) from those expressed or forecasted in the forward-looking statements.

These risks and uncertainties include, but are not limited to, those described in Part II, Item 1A “Risk Factors” and elsewhere in this report. Forward-looking statements that were believed to be true at the time made may ultimately prove to be incorrect or false. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.

PART I. FINANCIAL INFORMATION

ITEM 1.      FINANCIAL STATEMENTS

SWK HOLDINGS CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except par value and share data)

	March 31, 2019			December 31, 2018
ASSETS
Cash and cash equivalents	$	39,183		$	20,227
Interest receivable		1,930			2,195
Finance receivables, net		154,410			166,610
Corporate debt securities		511			532
Deferred tax asset		21,573			22,684
Warrant assets		3,057			2,777
Other assets		645			637
Total assets	$	221,309		$	215,662
Commitments and contingencies (Note 7)
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts payable and accrued liabilities	$	2,301		$	2,592
Warrant liability		35			13
Total liabilities		2,336			2,605
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively		—			—
Common stock, $0.001 par value; 250,000,000 shares authorized; 12,898,599 and 12,933,674 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively		13			13
Additional paid-in capital		4,431,856			4,432,499
Accumulated deficit		(4,212,896	)		(4,219,455	)
Total stockholders’ equity		218,973			213,057
Total liabilities and stockholders’ equity	$	221,309		$	215,662

See accompanying notes to the unaudited condensed consolidated financial statements.

1

SWK HOLDINGS CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(in thousands, except per share data)

	Three Months Ended March 31,
	2019		2018
Revenues:
Finance receivable interest income, including fees	$	9,391	$	6,817
Other		1		5
Total revenues		9,392		6,822
Costs and expenses:
Provision for credit losses		609		1,179
Interest expense		102		—
General and administrative		1,269		1,221
Total costs and expenses		1,980		2,400
Other income (expense), net
Unrealized net gain on warrants		258		300
Unrealized net loss on equity securities		—		(124	)
Income before provision for income taxes		7,670		4,598
Provision for income taxes		1,111		954
Consolidated net income	$	6,559	$	3,644
Net income per share
Basic	$	0.51	$	0.28
Diluted	$	0.51	$	0.28
Weighted Average Shares
Basic		12,906		13,053
Diluted		12,909		13,057

See accompanying notes to the unaudited condensed consolidated financial statements.

2

SWK HOLDINGS CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in thousands)

	Three Months Ended March 31,
	2019		2018
Consolidated net income	$	6,559	$	3,644
Other comprehensive income, net of tax		—		—
Comprehensive income	$	6,559	$	3,644

See accompanying notes to the unaudited condensed consolidated financial statements.

3

SWK HOLDINGS CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands, except share data)

	Three Months Ended March 31, 2019
	Common Stock					Additional Paid-In Capital			Accumulated Deficit			Accumulated Other Comprehensive Income		Total Stockholders’ Equity
	Shares			Amounts
Balances at December 31, 2018		12,933,674		$	13	$	4,432,499		$	(4,219,455	)	$	—	$	213,057
Stock-based compensation		—			—		102			—			—		102
Issuance of common stock		42,225			—		—			—			—		—
Repurchases of common stock in open market		(77,300	)				(745	)		—			—		(745	)
Net income		—			—		—			6,559			—		6,559
Balances at March 31, 2019		12,898,599		$	13	$	4,431,856		$	(4,212,896	)	$	—	$	218,973

	Three Months Ended March 31, 2018
	Common Stock				Additional Paid-In Capital		Accumulated Deficit			Accumulated Other Comprehensive Income (Loss)			Total Stockholders’ Equity
	Shares		Amounts
Balances at December 31, 2017		13,053,422	$	13	$	4,433,589	$	(4,225,863	)	$	213		$	207,952
Stock-based compensation		—		—		79		—			—			79
Issuance of common stock		5,768		—		—		—			—			—
Repurchases of common stock in open market		—		—		—		—			—			—
Cumulative effect of adoption of ASU 2016-01		—		—		—		213			(213	)		—
Net income		—		—		—		3,644			—			3,644
Balances at March 31, 2018		13,059,190	$	13	$	4,433,668	$	(4,222,006	)	$	—		$	211,675

See accompanying notes to the consolidated financial statements.

4

SWK HOLDINGS CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

	Three Months Ended March 31,
	2019			2018
Cash flows from operating activities:
Consolidated net income	$	6,559		$	3,644
Adjustments to reconcile net income to net cash provided by operating activities:
Provision for loan credit losses		609			1,179
Deferred income taxes		1,111			954
Change in fair value of warrants		(258	)		(300	)
Change in fair value of equity securities		—			124
Loan discount amortization and fee accretion		(600	)		(837	)
Interest paid-in-kind		(406	)		(47	)
Stock-based compensation		102			79
Interest income in excess of cash received		(81	)		(70	)
Other		(1	)		4
Changes in operating assets and liabilities:
Interest receivable		265			58
Other assets		(9	)		(189	)
Accounts payable and other liabilities		(291	)		610
Net cash provided by operating activities		7,000			5,209
Cash flows from investing activities:
Investment in finance receivables		(11,186	)		(29,250	)
Repayment of finance receivables		23,866			14,918
Corporate debt security principal payment		21			19
Other		—			(2	)
Net cash provided by (used in) investing activities		12,701			(14,315	)
Cash flows from financing activities:
Repurchases of common stock, including fees and expenses		(745	)		—
Net cash used in financing activities		(745	)		—
Net increase (decrease) in cash and cash equivalents		18,956			(9,106	)
Cash and cash equivalents at beginning of period		20,227			30,557
Cash and cash equivalents at end of period	$	39,183		$	21,451

See accompanying notes to the unaudited condensed consolidated financial statements.

5

SWK HOLDINGS CORPORATION

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note 1. SWK Holdings Corporation and Summary of Significant Accounting Policies

Nature of Operations

SWK Holdings Corporation (the “Company”) was incorporated in July 1996 in California and reincorporated in Delaware in September 1999. In July 2012, the Company commenced its strategy of building a specialty finance and asset management business. The Company’s strategy is to be a leading healthcare capital provider by offering sophisticated, customized financing solutions to a broad range of life science companies, institutions and inventors. The Company is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. The Company has been deploying its assets to earn interest, fees, and other income pursuant to this strategy, and the Company continues to identify and review financing and similar opportunities on an ongoing basis. In addition, through the Company’s wholly-owned subsidiary, SWK Advisors LLC, the Company provides non-discretionary investment advisory services to institutional clients in separately managed accounts to similarly invest in life science finance. SWK Advisors LLC is registered as an investment advisor with the Texas State Securities Board. The Company intends to fund transactions through its own working capital, and its revolving credit facility, as well as by building its asset management business by raising additional third-party capital to be invested alongside the Company’s capital.

The Company fills a niche that it believes is underserved in the sub-$50 million transaction size. Since many of its competitors that provide longer term, non-traditional debt and/or royalty-related financing options have much greater financial resources than the Company, they tend to not focus on transaction sizes below $50 million as it is generally inefficient for them to do so. In addition, the Company does not believe that a sufficient number of other companies offer similar types of long-term financing options to fill the demand of the sub-$50 million market. As such, the Company believes it faces less competition from such investors in transactions that are less than $50 million.

The Company has net operating loss carryforwards (“NOLs”) and believes that the ability to utilize these NOLs is an important and substantial asset. However, at this time, under current law, we do not anticipate that our life science business strategy will generate sufficient income to permit us to utilize all of our NOLs prior to their respective expiration dates. As such, it is possible that we might pursue additional strategies that we believe might result in our ability to utilize more of our NOLs.

As of May 9, 2019, the Company and its partners have executed transactions with 34 different parties under its specialty finance strategy, funding an aggregate $499 million in various financial products across the life science sector. The Company’s portfolio includes senior and subordinated debt backed by royalties and synthetic royalties paid by companies in the life science sector, and purchased royalties generated by sales of life science products and related intellectual property.

The Company is headquartered in Dallas, Texas.

Basis of Presentation and Principles of Consolidation

The Company’s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”).  The consolidated financial statements include the accounts of all subsidiaries and affiliates in which the Company holds a controlling financial interest as of the financial statement date. Normally a controlling financial interest reflects ownership of a majority of the voting interests. The Company consolidates a variable interest entity (“VIE”) when it possesses both the power to direct the activities of the VIE that most significantly impact its economic performance and the Company is either obligated to absorb the losses that could potentially be significant to the VIE or the Company holds the right to receive benefits from the VIE that could potentially be significant to the VIE, after elimination of intercompany accounts and transactions.

The Company owns interests in various partnerships and limited liability companies, or LLCs. The Company consolidates its investments in these partnerships or LLCs, where the Company, as the general partner or managing member, exercises effective control, even though the Company’s ownership may be less than 50 percent, the related governing agreements provide the Company with broad powers, and the other parties do not participate in the management of the entities and do not effectively have the ability to remove the Company. The Company has reviewed each of the underlying agreements to determine if it has effective control. If circumstances change and it is determined this control does not exist, any such investment would be recorded using the equity method of accounting. Although this would change individual line items within the Company’s consolidated financial statements, it would have no effect on its operations and/or total stockholders’ equity attributable to the Company.

6

Unaudited Interim Financial Information

The unaudited condensed consolidated financial statements have been prepared by the Company and reflect all normal, recurring adjustments that, in the opinion of management, are necessary for a fair presentation of the interim financial information. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for any subsequent quarter or for the year ending December 31, 2019. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted under the rules and regulations of the Securities and Exchange Commission (“SEC”). These unaudited condensed consolidated financial statements and notes included herein should be read in conjunction with the audited consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 28, 2019.

Use of Estimates

The preparation of the Company’s consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are required in the determination of revenue recognition, stock-based compensation, impairment of financing receivables and long-lived assets, valuation of warrants, income taxes and contingencies and litigation, among others.  Some of these judgments can be subjective and complex, and consequently, actual results may differ from these estimates. The Company’s estimates often are based on complex judgments, probabilities and assumptions that it believes to be reasonable but that are inherently uncertain and unpredictable. For any given individual estimate or assumption made by the Company, there may also be other estimates or assumptions that are reasonable.

The Company regularly evaluates its estimates and assumptions using historical experience and other factors, including the economic environment. As future events and their effects cannot be determined with precision, the Company’s estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause changes to those estimates and assumptions. Market conditions, such as illiquid credit markets, volatile equity markets, and economic downturns, can increase the uncertainty already inherent in the Company’s estimates and assumptions. The Company adjusts its estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our consolidated financial statements on a prospective basis unless they are required to be treated retrospectively under the relevant accounting standard. It is possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts.

Recent Accounting Pronouncements

In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2018-13, “Fair Value Measurement (Topic 820) - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement.” ASU 2018-13 updates the fair value measurement disclosure requirements by (i) eliminating certain requirements, including disclosure of the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, the policy for timing of transfers between levels and the valuation processes for Level 3 fair value measurements, (ii) modifying certain requirements, including clarifying that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date and (iii) adding certain requirements, including disclosure of the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. ASU 2018-13 is effective for fiscal years and interim periods within those years beginning after December 15, 2019, with early adoption permitted for any eliminated or modified disclosures. The Company is currently evaluating the new guidance but believes it will not have a material impact on its consolidated financial statements, as the Company has had no historical transfers between hierarchies.

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic 326).” The new standard adds an impairment model, known as the current expected credit loss (“CECL”) model, that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes as an allowance its estimate of expected credit losses, which the FASB believes will result in more timely recognition of losses. The ASU describes the impairment allowance as a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. Credit losses relating to available-for-sale debt securities should be measured in a manner similar to current GAAP; however, the amendments in this update require that credit losses be presented as an allowance rather than as a write-down, which will allow an entity the ability to record reversals of credit losses in current period net income. The amendments in this update are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. An entity will apply the amendments in this update through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective (that is, a modified-retrospective approach). A prospective transition approach is required for debt securities for which an other-than-temporary impairment has been recognized before the effective date. The Company is currently evaluating the new guidance but believes it is likely to incur more upfront losses on its portfolio under the new CECL model.

In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, Leases, as amended by subsequent ASUs (Topic 842). ASU 2016-02 supersedes guidance related to accounting for leases and provides for the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. The objective of the ASU is to establish the principles that lessees and lessors shall apply to report useful information to users of financial statements about the amount, timing and uncertainty of cash flows arising from a lease. ASU 2016-02 does not fundamentally change lessor accounting; however, some changes have been made to lessor accounting to conform and align that guidance with the lessee guidance and other areas within GAAP. The ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2018, with early adoption permitted. The Company elected to adopt ASU 2016-02 on January 1, 2019 using the modified retrospective transition method, which permits application of the new standard on the adoption date as opposed to the earliest comparative period presented in the financial statements. In addition, the Company elected to use the available practical expedient package, and therefore did not reassess classification of its existing leases. The adoption of this ASU did not have a material impact on the Company’s consolidated financial statements. 

7

Note 2. Net Income per Share

Basic net income per share is computed using the weighted-average number of outstanding shares of common stock. Diluted net income per share is computed using the weighted-average number of outstanding shares of common stock, and when dilutive, shares of common stock issuable upon exercise of options and warrants deemed outstanding using the treasury stock method.

The following table shows the computation of basic and diluted net income per share for the following periods (in thousands, except per share amounts):

	Three Months Ended March 31,
	2019		2018
Numerator:
Net income	$	6,559	$	3,644
Denominator:
Weighted-average shares outstanding		12,906		13,053
Effect of dilutive securities		3		4
Weighted-average diluted shares		12,909		13,057
Basic net income per share	$	0.51	$	0.28
Diluted net income per share	$	0.51	$	0.28

For the three months ended March 31, 2019 and 2018, outstanding stock options and warrants to purchase shares of common stock in an aggregate of approximately 400,000 and 286,000, respectively, have been excluded from the calculation of diluted net income per share as all such securities were anti-dilutive.

8

Note 3. Finance Receivables, Net

Finance receivables are reported at their determined principal balances net of any unearned income, cumulative charge-offs and unamortized deferred fees and costs. Unearned income and deferred fees and costs are amortized to interest income based on all cash flows expected using the effective interest method.

As of March 31, 2019, the Company had a provision for credit loss allowance of $6.8 million. Of the total $6.8 million, $1.2 million and $0.6 million are associated with the Company’s Cambia® and Besivance® royalties, respectively. The remaining $5.0 million is related to the ABT Molecular Imaging, Inc., now known as Best ABT, Inc. (“Best”), second lien term loan that was recognized in order to reflect the Best royalty at its estimated fair value of $5.8 million. The carrying value of finance receivables are as follows (in thousands):

Portfolio	March 31, 2019			December 31, 2018
Term loans	$	127,689		$	136,379
Royalty purchases		33,509			36,410
Total before allowance for credit losses		161,198			172,789
Allowance for credit losses		(6,788	)		(6,179	)
Total carrying value	$	154,410		$	166,610

The following table presents nonaccrual and performing finance receivables by portfolio segment, net of credit loss allowance (in thousands):

	March 31, 2019						December 31, 2018
	Nonaccrual		Performing		Total		Nonaccrual		Performing		Total
Term loans	$	8,337	$	119,352	$	127,689	$	8,337	$	128,042	$	136,379
Royalty purchases, net of credit loss allowance		5,784		20,937		26,721		5,784		24,447		30,231
Total carrying value	$	14,121	$	140,289	$	154,410	$	14,121	$	152,489	$	166,610

As of March 31, 2019 and December 31, 2018, the Company had two finance receivables in nonaccrual status: (a) the term loan to B&D Dental Corporation (“B&D”), with a net carrying value of $8.3 million at each date, and (b) the Best royalty, with a net carrying value of $5.8 million at each date. Although in nonaccrual status, neither the term loan nor royalty were considered impaired as of March 31, 2019. The Company did not collect any cash on nonaccrual items during the three months ended March 31, 2019. 

Besivance

On April 2, 2013, the Company purchased an effective 2.4 percent royalty on sales of Besivance® from InSite Vision for $6.0 million. Besivance is marketed by Bausch & Lomb, formerly known as Valeant Pharmaceuticals. Recently the sales performance of Besivance® has weakened primarily due to substantial declines in prescription volumes, which in conjunction with elevated sales chargebacks and various rebates (gross sales to net sales deductions), has resulted in material reductions in the product’s net sales and associated royalties payable to the Company. During the three months ended March 31, 2019, the Company reduced its expectations for future royalty receipts and recognized an allowance for credit loss on the royalty purchase of $0.6 million.

9

Note 4. Marketable Investments

Investments in marketable securities at March 31, 2019 and December 31, 2018 consist of the following (in thousands):

	March 31, 2019		December 31, 2018
Corporate debt securities	$	511	$	532

The amortized cost basis amounts, gross unrealized holding gains, gross unrealized holding losses and fair values of available-for-sale debt securities as of March 31, 2019 and December 31, 2018, are as follows (in thousands):

March 31, 2019	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Loss		Fair Value
Corporate debt securities	$	511	$	—	$	—	$	511

December 31, 2018	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Loss		Fair Value
Corporate debt securities	$	532	$	—	$	—	$	532

The following table presents unrealized net losses on equity securities as prescribed by ASC 321, “Investment - Equity Securities.” ASU 2016-01, “Recognition and Measurement of Financial Assets and Financial Liabilities,” was adopted on January 1, 2018, at which time a cumulative effect adjustment of $213,000 was recorded to reclassify the amount of accumulated unrealized gains related to equity securities from accumulated other comprehensive income to retained earnings (in thousands):

	Three Months Ended March 31,
	2019		2018
Unrealized net loss on equity securities reflected in the Unaudited Condensed Consolidated Statements of Income	$	—	$	(124	)

Equity Securities

The Company did not have any investments in equity securities as of March 31, 2019.

As of March 31, 2018, the Company’s equity securities included 661,076 shares of Cancer Genetics and Hooper Holmes common stock, which were sold and written off, respectively, during the year ended December 31, 2018.

Debt Securities

On July 9, 2013, the Company entered into a note purchase agreement to purchase, at par, $3.0 million of a total of $100.0 million aggregate principal amount of senior secured notes due in November 2026. The agreement allows the first interest payment date to include paid-in-kind notes for any cash shortfall, of which the Company received $0.1 million on November 15, 2013. The notes are secured only by certain royalty and milestone payments associated with the sales of pharmaceutical products. The senior secured notes have been placed on non-accrual status as of June 30, 2016. Total cash collected during the three months ended March 31, 2019 was $21,000 which was credited to the notes’ carrying value. As of March 31, 2019, the notes are reflected at their estimated fair value of $0.5 million.

Note 5. Revolving Credit Facility

On June 29, 2018, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with State Bank and Trust Company as a lender and the administrative agent (“State Bank”) pursuant to which State Bank will provide the Company with up to a $20 million revolving senior secured credit facility, which the Company can draw down and repay until maturity, subject to borrowing base eligibility. The Loan Agreement matures on June 29, 2021.

10

The Loan Agreement accrues interest at the Daily LIBOR Rate, with a floor of 1.00 percent, plus a 3.25 percent margin and principal is repayable in full at maturity. Interest is generally required to be paid monthly in arrears. The Loan Agreement requires the payment of an unused line fee of 0.50 percent, which will be recorded as interest expense. The Company paid $0.5 million in fees at closing, which have been capitalized as deferred financing costs and will be amortized on a straight-line basis over the term of the Loan Agreement.

The Loan Agreement has an advance rate against the Company’s finance receivables portfolio, including 85 percent against senior first lien loans, 70 percent against second lien loans and 50 percent against royalty receivables, subject to certain eligibility requirements as defined in the Loan Agreement. The Loan Agreement contains certain affirmative and negative covenants including minimum asset coverage and minimum interest coverage ratios.

During the three months ended March 31, 2019, the Company recognized $0.1 million of interest expense. As of March 31, 2019, no amount was outstanding under the Loan Agreement, and $20 million was available for borrowing.

11

Note 6. Related Party Transactions

On September 6, 2013, in connection with entering into a credit facility, the Company issued warrants to an affiliate of a stockholder, Carlson Capital, L.P. (the “Stockholder”), for 100,000 shares of the Company’s common stock at a strike price of $13.88 per share. The warrants have a price anti-dilution mechanism that was triggered by the price that shares were sold by the Company in a rights offering in 2014, and as a result, the strike price of the warrants was reduced to $13.48 per share.

Due to certain provisions within the warrant agreement, the warrants meet the definition of a derivative and do not qualify for a scope exception, as it is not considered indexed to the Company’s stock. As such, the warrants are reflected as a warrant liability in the unaudited condensed consolidated balance sheets. The Company recorded a nominal gain for the three months ended March 31, 2019. The Company determined the fair value using the Black-Scholes option pricing model with the following assumptions:

	March 31, 2019			December 31, 2018
Dividend rate		—			—
Risk-free rate		2.4	%		2.5	%
Expected life (years)		1.4			1.7
Expected volatility		23.7	%		18.6	%

The changes on the value of the warrant liability during the three months ended March 31, 2019 were as follows (in thousands):

Fair value – December 31, 2018	$	13
Issuances		—
Changes in fair value		22
Fair value – March 31, 2019	$	35

12

Note 7. Commitments and Contingencies

As of March 31, 2019, the Company’s unfunded commitments were as follows (in millions):

Aimmune Therapeutics, Inc.	$	3.8
Veru, Inc.		2.0
Total unfunded commitments	$	5.8

All unfunded commitments are contingent upon reaching an established revenue threshold or other performance metrics on or before a specified date or period of time per the terms of the royalty purchase or credit agreements, and in the case of loan transactions, are only subject to being advanced as long as an event of default does not exist.

Note 8. Stockholders’ Equity

Stock Compensation Plans

During the three months ended March 31, 2019 and 2018, the Company’s Board of Directors (the “Board”) approved compensation for Board services by granting 4,725 and 5,768 shares, respectively, of common stock as compensation for the non-employee directors. During both the three months ended March 31, 2019 and 2018, the Company recorded approximately $47,000 and $62,000 in Board stock-based compensation expense. The aggregate stock-based compensation expense, including the quarterly Board grants, recognized by the Company for both of the three months ended March 31, 2019 and 2018 was $0.1 million.

The Company’s Chief Executive Officer, (“CEO”) received a grant of options to acquire up to 75,000 shares of the Company’s common stock, effective as of January 28, 2019. The options have a per-share exercise price of $12.50. The options are subject to vesting in equal annual installments over a three-year period based on the CEO’s continued employment with the Company. The options are subject to accelerated vesting upon a termination of the CEO’s employment if the CEO’s employment is terminated by the CEO for “Good Reason” as defined in the CEO’s employment agreement effective as of January 1, 2019. Furthermore, the 2012 and 2014 options received by the CEO were amended to extend the expiration dates to December 31, 2021. The options are forfeited and of no force and effect to the extent the options have not vested or become exercisable on or before December 31, 2021.

The CEO also received a restricted stock award of 37,500 shares of restricted stock, subject to terms and conditions of the award agreement and the 2010 Stock Incentive Plan. The restricted stock is subject to vesting in equal annual installments over a three-year period but only to the extent the CEO is employed by or performing services for the Company. However, the restricted stock shall vest upon the CEO’s death, “Disability” and “Good Reason,” as defined in the Employment Agreement between the Company and the CEO effective January 1, 2019.

On December 21, 2018, the Board of Directors of the Company authorized a stock repurchase program, which is fully described in Part II, Item 2 under Unregistered Sales of Equity Securities and Use of Proceeds. The maximum number of shares that may yet be purchased under the plan is 174,691 as of March 31, 2019.

13

Note 9. Fair Value Measurements

The Company measures and reports certain financial and non-financial assets and liabilities on a fair value basis. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). GAAP specifies a three-level hierarchy that is used when measuring and disclosing fair value. The fair value hierarchy gives the highest priority to quoted prices available in active markets (i.e., observable inputs) and the lowest priority to data lacking transparency (i.e., unobservable inputs). An instrument’s categorization within the fair value hierarchy is based on the lowest level of significant input to its valuation. The following is a description of the three hierarchy levels.

Level 1	Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Active markets are considered to be those in which transactions for the assets or liabilities occur in sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2	Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability. This category includes quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in inactive markets.
Level 3	Unobservable inputs are not corroborated by market data. This category is comprised of financial and non-financial assets and liabilities whose fair value is estimated based on internally developed models or methodologies using significant inputs that are generally less readily observable from objective sources.

Transfers into or out of any hierarchy level are recognized at the end of the reporting period in which the transfers occurred. There were no transfers between any levels during the three months ended March 31, 2019.

The following information is provided to help readers gain an understanding of the relationship between amounts reported in the accompanying unaudited condensed consolidated financial statements and the related market or fair value. The disclosures include financial instruments and derivative financial instruments, other than investment in affiliates.

Following are descriptions of the valuation methodologies used to measure material assets and liabilities at fair value and details of the valuation models, key inputs to those models and significant assumptions utilized.

Cash and cash equivalents

The carrying amounts reported in the balance sheet for cash and cash equivalents approximate those assets’ fair values.

Equity Securities

Certain common equity securities are reported at fair value utilizing Level 1 inputs (exchange quoted prices).

Finance Receivables

The fair values of finance receivables are estimated using discounted cash flow analyses, using market rates at the balance sheet date that reflect the credit and interest rate-risk inherent in the finance receivables. Projected future cash flows are calculated based upon contractual maturity or call dates, projected repayments and prepayments of principal. These receivables are classified as Level 3. Finance receivables are not measured at fair value on a recurring basis, but estimates of fair value are reflected below.

Marketable Investments and Derivative Securities

Marketable Investments

If active market prices are available, fair value measurement is based on quoted active market prices and, accordingly, these securities would be classified as Level 1. If active market prices are not available, fair value measurement is based on observable inputs other than quoted prices included within Level 1, such as prices for similar assets or broker quotes utilizing observable inputs, and accordingly these securities would be classified as Level 2. If market prices are not available and there are no observable inputs, then fair value would be estimated by using valuation models including discounted cash flow methodologies, commonly used option-pricing models and broker quotes. Such securities would be classified as Level 3, if the valuation models and broker quotes are based on inputs that are unobservable in the market. If fair value is based on broker quotes, the Company checks the validity of received prices based on comparison to prices of other similar assets and market data such as relevant bench mark indices. Available-for-sale securities are measured at fair value on a recurring basis, while securities with no readily available fair market value are not, but estimates of fair value are reflected below.

14

Derivative Securities

For exchange-traded derivatives, fair value is based on quoted market prices, and accordingly, would be classified as Level 1. For non-exchange traded derivatives, fair value is based on option pricing models and are classified as Level 3.

The following table presents financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2019 (in thousands):

	Total Carrying Value in Consolidated Balance Sheet		Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Financial Assets:
Warrant assets	$	3,057	$	—	$	—	$	3,057
Corporate debt securities		511		—		—		511
Financial Liabilities:
Warrant liability	$	35	$	—	$	—	$	35

The following table presents financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2018 (in thousands):

	Total Carrying Value in Consolidated Balance Sheet		Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Financial Assets:
Warrant assets	$	2,777	$	—	$	—	$	2,777
Corporate debt securities		532		—		—		532
Financial Liabilities:
Warrant liability	$	13	$	—	$	—	$	13

The changes on the value of the warrant assets during the three months ended March 31, 2019 were as follows (in thousands):

Fair value – December 31, 2018	$	2,777
Issued		—
Canceled		—
Change in fair value		280
Fair value – March 31, 2019	$	3,057

15

The Company holds warrants issued to the Company in conjunction with certain term loan investments. These warrants meet the definition of a derivative and are included in the unaudited condensed consolidated balance sheets. The fair values for warrants outstanding, which do not have a readily determinable value, are measured using the Black-Scholes option pricing model. The following ranges of assumptions were used in the models to determine fair value:

	March 31, 2019		December 31, 2018
Dividend rate range		—		—
Risk-free rate range		2.2% to 2.3%		2.5% to 2.6%
Expected life (years) range		4.5 to 7.6		4.8 to 7.9
Expected volatility range		68.8% to 84.6%		67.6% to 101.8%

As of March 31, 2019 and December 31, 2018, the Company had two royalties, Besivance® and Cambia®, that were deemed to be impaired. The following table presents these royalties measured at fair value on a nonrecurring basis as of March 31, 2019 and December 31, 2018 (in thousands):

	Total Carrying Value in Consolidated Balance Sheet		Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
March 31, 2019
Impaired royalties	$	7,160	$	—	$	—	$	7,160
December 31, 2018
Impaired royalties	$	8,227	$	—	$	—	$	8,227

There were no liabilities measured at fair value on a nonrecurring basis as of March 31, 2019 and December 31, 2018.

The following information is provided to help readers gain an understanding of the relationship between amounts reported in the accompanying unaudited condensed consolidated financial statements and the related market or fair value. The disclosures include financial instruments and derivative financial instruments.

As of March 31, 2019 (in thousands):

	Carry Value		Fair Value		Level 1		Level 2		Level 3
Financial Assets
Cash and cash equivalents	$	39,183	$	39,183	$	39,183	$	—	$	—
Finance receivables		154,410		154,410		—		—		154,410
Marketable investments		511		511		—		—		511
Warrant assets		3,057		3,057		—		—		3,057
Financial Liabilities
Warrant liability	$	35	$	35	$	—	$	—	$	35

As of December 31, 2018 (in thousands):

	Carry Value		Fair Value		Level 1		Level 2		Level 3
Financial Assets
Cash and cash equivalents	$	20,227	$	20,227	$	20,227	$	—	$	—
Finance receivables		166,610		166,610		—		—		166,610
Marketable investments		532		532		—		—		532
Warrant assets		2,777		2,777		—		—		2,777
Financial Liabilities
Warrant liability	$	13	$	13	$	—	$	—	$	13

16

Note 10. Subsequent Events

Solsys Medical LLC

On May 2, 2019, Misonix, Inc. (“Misonix”) announced it had entered into a definitive agreement with one of our partner companies, Solsys Medical LLC (“Solsys”), to acquire Solsys in an all-stock transaction valued at approximately $97 million. Concurrent with the announcement, SWK Funding LLC (“SWK Funding”) executed (i) an amendment with Solsys to provide up to $5 million of additional capital under the credit agreement, with $2.5 million funded at closing of the amendment, and $2.5 million eligible to be drawn upon Solsys raising at least $4 million of additional equity capital prior to the merger, and (ii) a Commitment Letter with Misonix that allows Misonix to assume the Solsys credit facity whereby SWK Funding would become the senior secured lender to the surviving parent entity upon consummation of the merger. Pursuant to the Commitment Letter, SWK Funding agreed to extend the credit facility’s maturity date and interest only period, and to decrease the interest rate from Libor plus 10.5 percent to a range of Libor plus 7 to 9 percent, dependent upon certain financial metrics. SWK Funding also agreed to provide an additional $5 million of add-on term loan funding, drawable at Misonix’s option until the first anniversary of the consummation of the merger with Solsys. Misonix’s merger with SolSys is subject to the approval of both companies’ shareholders and is expected to be completed in the third quarter of calendar year 2019.

BIOLASE, Inc.

On May 7, 2019, SWK Funding executed an amendment with BIOLASE, Inc. (“BIOLASE”) whereby SWK Funding agreed to fund an additional $2.5 million under the credit agreement to support the company’s growth initiatives.

Veru, Inc.

On May 13, 2019, SWK Funding executed an amendment with Veru, Inc. (“Veru”), whereby the royalty rates applicable to sales of FC2 Female Condom (“FC2”), the business upon which SWK Funding receives its quarterly royalties, were reduced by 50 percent for the next four payment periods to accommodate Veru’s growth working capital needs. The royalty rates return to the original levels in 2020 and subsequently increase in 2021 in accordance with the terms outlined in the amendment. Furthermore, upon the credit agreement’s termination date of March 5, 2025, the amount Veru must pay was increased to 176.25 percent of the aggregate amount advanced, less the amounts previously paid from product revenue, less the outstanding principal amount of the loans as of such date; however, the residual royalty payable to SWK Funding upon achieving the maximum threshold will commence based on the pre-amendment royalty rates. The $2.0 million unfunded commitment was also eliminated.

17

ITEM 2.      MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is provided as a supplement to, and should be read in conjunction with, our audited consolidated financial statements, and the MD&A included in our Annual Report on Form 10-K for the year ended December 31, 2018 (“Annual Report”), as well as our unaudited condensed consolidated financial statements and the accompanying notes included in this report.

Overview

We evaluate and invest in a broad range of healthcare related companies and products with innovative intellectual property, including the biotechnology, medical device, medical diagnostics and related tools, animal health and pharmaceutical industries (together “life science”) by tailoring financial solutions to the needs of our business partners.

Our investment objective is to maximize our portfolio total return and thus increase our net income and book value by generating income from three sources: (1) primarily owning or financing through debt investments, royalties or revenue interests generated by the sales of life science products and related intellectual property, (2) receiving interest and other income by advancing capital in the form of secured debt to companies in the life science sector, and (3) to a lesser extent, realizing capital appreciation from equity-related investments in the life science sector.

We primarily provide capital in exchange for an interest in an existing revenue stream, which can take several forms, but is most commonly either a royalty derived from the sales of a life science product from the marketing efforts of a third party or from the marketing efforts of a partner company. Our structured debt investments may include warrants or other features, giving us the potential to realize enhanced returns on a portion of our portfolio.

The table below provides an overview of our outstanding transactions as of, and for the three months ended March 31, 2019 (in thousands, except rate, share and per share data):

Royalty Purchases and Financings	License Technology	Footnote	Funded Amount		GAAP Balance		Rate	Revenue Recognized
								Q1
Beleodaq®	Oncology treatment		$	7,600	$	7,037	N/A	$	314
Besivance®	Ophthalmic antibiotic	(1), (2)	6,000		1,401		N/A	14
Best ABT, Inc.	Oncology diagnosis	(3)	5,784		5,784		N/A	—
Cambia®	NSAID migraine treatment	(2)	8,500		5,759		N/A	228
Forfivo XL®	Depressive disorder treatment		6,000		2,534		N/A	439
Narcan®	Opioid overdose treatment		17,500		654		N/A	418
Secured Royalty Financing (Corporate Debt Security)	Women’s health	(3)	3,000		511		11.5%	—
Tissue Regeneration Therapeutics	Umbilical cord banking		3,250		3,553		N/A	110

18

			Maturity			GAAP			Revenue Recognized
Term Loans	Type	Footnote	Date	Principal		Balance		Rate	Q1
Acerus Pharmaceuticals, Inc.	First Lien		10/11/23	$	9,000	$	8,250	12.0%	$	360
Aimmune Therapeutics, Inc.	First Lien		12/31/24	1,201		1,203		8.5%	18
B&D Dental Corporation	First Lien	(3), (4)	12/10/18	8,368		8,337		14.0%	—
B&D Dental Corporation	First Lien Equipment Loan	(4)	03/31/20	34		34		16.3%	2
BIOLASE, Inc.	First Lien	(5)	11/09/23	12,500		11,988		12.3%	464
CeloNova BioSciences, Inc.	First Lien		07/31/21	6,311		6,393		13.0%	283
Cheetah Medical, Inc.	First Lien		01/15/24	10,000		9,730		10.8%	344
DxTerity Diagnostics, Inc.	First Lien	(6)	04/06/20	9,618		9,774		13.3%	387
Epica International, Inc.	First Lien		07/23/23	12,200		12,164		10.5%	373
EyePoint Pharmaceuticals, Inc.	First Lien	(7)	03/27/23	—		—		12.0%	3,454
Harrow Health, Inc. (formerly Imprimis Pharmaceuticals)	First Lien		07/19/21	9,264		9,029		12.0%	376
Keystone Dental, Inc.	First Lien		05/20/21	15,000		15,155		11.5%	542
Solsys Medical LLC	First Lien	(8)	10/26/22	15,096		15,285		11.8%	525
Tenex Health, Inc.	First Lien		06/30/21	7,259		7,367		13.0%	303
Thermedx, LLC	First Lien		05/05/21	3,500		4,377		N/A	15
Veru, Inc.	First Lien		03/05/25	10,000		8,602		N/A	422

		Number of	Exercise Price per	GAAP		Change in Fair Value
Warrants to Purchase Stock	Footnote	Shares	Share	Balance		Q1
Acerus Pharmaceuticals, Inc.		5,331,563	0.40 CAD	$	284	$	116
B&D Dental Corporation		225	0.01			—
BIOLASE, Inc.		372,023	1.34	742		469
CeloNova BioSciences, Inc.		TBD	0.01	—		—
Cheetah Medical, Inc.		1,578,948	0.38	—		—
DxTerity Diagnostics, Inc.		686,058	2.08	—		—
Epica International, Inc.		TBD	TBD	—		—
EyePoint Pharmaceuticals, Inc. (Tranche 1)		409,091	1.10	527		(42		)
EyePoint Pharmaceuticals, Inc. (Tranche 2)		77,721	1.93	87		(8		)
Harrow Health, Inc. (formerly Imprimis Pharmaceuticals)		373,847	2.08	1,417		(255		)
Keystone Dental, Inc.		793,651	1.26	—		—
Solsys Medical LLC		1,209,068	0.99	—		—
Solsys Medical LLC		2,284,793	0.98	—		—
Tenex Health, Inc.		2,693,878	0.37	—		—

19

			Revenue Recognized
	Assets		Q1
Total Finance Receivables	$	154,410	$	9,391
Total Corporate Debt Securities	511		—
Fair Value of Warrant Assets	3,057		—
Total Assets/Revenues	$	157,978	$	9,391

(1)	Provision for credit losses of $609 recognized during the quarter.
(2)	Investment considered impaired.
(3)	Investment on nonaccrual.
(4)	B&D is evaluating strategic alternatives for the business. The loan is currently in default.
(5)	Executed amendment May 7, 2019 to fund an additional $2,500.
(6)	Executed amendment effective January 1, 2019 to allow DxTerity to pay in kind the interest payments due in January 2019 and April 2019, subject to DxTerity raising additional subordinated capital, which was completed.
(7)	EyePoint repaid the term loan on February 13, 2019, which included $3,454 of interest, deferred origination fees, prepayment, and exit fees.
(8)	Executed amendment May 2, 2019 and funded $2,500 at closing, with an additional $2,500 available upon Solsys raising $4,000 of equity capital. Entered into Commitment Letter with Misonix to allow Misonix to assume the credit facility upon closing of the Solsys merger, and to provide for an additional $5,000 term loan to be available to Misonix until the first anniversary of closing of the merger.
(9)	Executed amendment May 13, 2019 whereby the royalty rates applicable to FC2’s net sales were reduced by 50 percent for the next four payment periods to accommodate Veru’s growth working capital needs. The royalty rates return to the original levels in 2020 and subsequently increase in 2021. Total aggregate amount due by maturity was increased to 176.25 percent of the aggregate amount advanced.

Unless otherwise specified, our senior secured debt assets generally are repaid by a revenue interest that is charged on a company’s quarterly net sales and royalties.

20

Critical Accounting Policies and Estimates

Our critical accounting policies and estimates are described in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 28, 2019. We believe there have been no new critical accounting policies or material changes to our existing critical accounting policies and estimates during the three months ended March 31, 2019, compared to those discussed in our Annual Report on Form 10-K for the year ended December 31, 2018.

Recent Accounting Pronouncements

Refer to Part I. Financial Information, Item 1. Financial Statements, Note 1 of the Notes to the Unaudited Condensed Consolidated Financial Statements for a listing of recent accounting pronouncements and their potential impact to our consolidated financial statements.

Comparison of the Three Months Ended March 31, 2019 and 2018 (in millions)

	Three Months Ended March 31,				Change
	2019		2018
Revenues	$	9.4	$	6.8	$	2.6
Provision for credit losses and impairment expense	0.6		1.2		(0.6		)
Interest expense	0.1		—		0.1
General and administrative	1.3		1.2		0.1
Other income	0.3		0.2		0.1
Provision for income taxes	1.1		1.0		0.1
Consolidated net income	6.6		3.6		3.0

Revenues

We generated revenues of $9.4 million and $6.8 million for the three months ended March 31, 2019 and 2018, respectively, which consisted of interest and fees earned on our finance receivables. The increase in revenue is primarily due to a $2.5 million increase in interest and fees earned on new and existing finance receivables and $3.4 million in exit and prepayment fees from a loan payoff. The increase in revenue was offset by a $2.6 million decrease in interest and fees earned on finance receivables that were paid off or paid down in 2018.

Provision for Credit Losses and Impairment Expense

During the three months ended March 31, 2019, we recognized credit loss provision expense of $0.6 million related to the Besivance® royalty, which was due to increases in sales chargebacks and various rebates (gross sales to net sales deductions) and lower sales volumes. We recognized an allowance for credit losses on a royalty of $1.2 million during the three months ended March 31, 2018. Please refer to Part I. Financial Information, Item 1. Financial Statements, Note 3 of the Notes to the Unaudited Condensed Consolidated Financial Statements for further information on the provision for credit losses recognized during the three months ended March 31, 2019.

General and Administrative

General and administrative expenses consist primarily of compensation, stock-based compensation and related costs for management, staff, Board of Directors, legal and audit expenses, and corporate governance. General and administrative expenses increased to $1.3 million for the three months ended March 31, 2019 from $1.2 million for the three months ended March 31, 2018, which was primarily due to an increase in the performance-based bonus accrual.

Other Income (Expense), Net

Other income for the three months ended March 31, 2019 reflected a net fair market value gain of $0.3 million on our warrant derivatives. Other income for the three months ended March 31, 2018, reflected a net fair market value gain of $0.3 million on our warrant derivatives and a net fair market value loss of $0.1 million on our equity securities.

21

Income Tax (Benefit) Expense

We recognized deferred income tax expense of $1.1 million and $1.0 million during the three months ended March 31, 2019 and 2018, respectively. The increase in deferred income tax expense was primarily due to an increase in net income.

Liquidity and Capital Resources

As of March 31, 2019, we had $39.2 million in cash and cash equivalents, compared to $20.2 million in cash and cash equivalents as of December 31, 2018. The primary driver of the net increase in our cash balance was $23.3 million related to the payoff of one finance receivable, offset by new and add-on investment funding of $11.2 million.

Our ability to generate cash in the future depends primarily upon our success in implementing our business model of generating income by providing capital to a broad range of life science companies, institutions and inventors. We generate income primarily from three sources:

1. primarily owning or financing through debt investments, royalties generated by the sales of life science products and related intellectual property;

2. receiving interest and other income by advancing capital in the form of secured debt to companies in the life science sector; and,

3. to a lesser extent, realizing capital appreciation from equity-related investments in the life science sector.

As of March 31, 2019, our portfolio contains $154.4 million of finance receivables and $0.5 million of corporate debt securities. We expect these assets to generate positive cash flows in 2019. We continue to evaluate multiple attractive opportunities that, if consummated, we believe would similarly generate additional income. Since the timing of any investment is difficult to predict, we may not be able to generate positive cash flow above what our existing assets will produce in 2019.

We entered into a $20 million revolving credit facility in June 2018. We intend to borrow funds to make investments to the extent we determine that additional capital would allow us to take advantage of additional investment opportunities. The total undrawn amount of the credit facility as of March 31, 2019 was $20 million.

Off Balance Sheet Arrangements

In the normal course of operations, we engage in a variety of financial transactions that, in accordance with GAAP, are not recorded in our consolidated financial statements. These transactions involve, to varying degrees, elements of credit, interest rate, and liquidity risk. Such transactions are used primarily to manage partner companies’ requests for funding and take the form of loan commitments and lines of credit.

The contractual amounts of commitments to extend credit represent the amounts of potential accounting loss should the contract be fully drawn upon, the partner company defaults, and the value of any existing collateral becomes worthless. We use the same credit policies in making commitments and conditional obligations as we do for on-balance sheet instruments. Please refer to Note 7, “Commitments and Contingencies,” of the Notes to the Unaudited Condensed Consolidated Financial Statements in Item 1.

22

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

During the three months ended March 31, 2019, our cash and cash equivalents were deposited in accounts at well capitalized financial institutions. The fair value of our cash and cash equivalents at March 31, 2019 approximated its carrying value.

Investment and Interest Rate Risk

We are subject to financial market risks, including changes in interest rates. As we seek to provide capital to a broad range of life science companies, institutions and investors, our net investment income is dependent, in part, upon the difference between the rate at which we earn on our cash and cash equivalents and the rate at which we lend those funds to third parties. As a result, we would be subject to risks relating to changes in market interest rates. We may use interest rate risk management techniques in an effort to limit our exposure to interest rate fluctuations by providing capital at variable interest rates. We constantly monitor our portfolio and position our portfolio to respond appropriately to a reduction in credit rating of any of our investments.

During 2018, we entered into a revolving credit facility. As we borrow funds to make additional investments, our income will depend, in part, upon the difference between the rate at which we borrow funds and the rate at which we invest those funds. As a result, we are subject to risks relating to changes in market interest rates. In periods of rising interest rates when we have debt outstanding, our cost of funds would increase, which could reduce our income, especially to the extent we continue to hold fixed rate investments. If deemed prudent, we may use interest rate risk management techniques in an effort to minimize our exposure to interest rate fluctuations. Adverse developments resulting from changes in interest rates or hedging transactions could have a materially adverse effect on our business, financial condition and results of operations.

Inflation

We do not believe that inflation has had a significant impact on our revenues or operations.

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and that such information is accumulated and communicated to the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures.

In connection with the preparation of this report, our management, under the supervision and with the participation of the Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

Changes in Internal Control over Financial Reporting

There have been no changes during the three months ended March 31, 2019 in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

23

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are involved in, or have been involved in, arbitrations or various other legal proceedings that arise from the normal course of our business. We cannot predict the timing or outcome of these claims and other proceedings. The ultimate outcome of any litigation is uncertain, and either unfavorable or favorable outcomes could have a material negative impact on our results of operations, balance sheets and cash flows due to defense costs, and divert management resources. Currently, we are not involved in any arbitration and/or other legal proceeding that we expect to have a material effect on our business, financial condition, results of operations and cash flows.

ITEM 1A. RISK FACTORS.

Information regarding the Company’s risk factors appears in “Part I. – Item 1A. Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed with the SEC on March 28, 2019. There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

On December 21, 2018, the Board authorized a share repurchase program under which the Company may repurchase up to $3.5 million of the Company’s outstanding shares of common stock, or approximately 312,491 common shares, in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Securities Exchange Act. The purchase period is December 21, 2018 through May 31, 2019.

As of May 14, 2019, the Company has repurchased 222,366 shares of its outstanding shares of common stock. Of the total 222,366 shares, 137,800 were repurchased under the share repurchase program at a total cost of $1.3 million, or $9.58 per share. As of March 31, 2019, the maximum number of shares that may yet be purchased under the plan is 174,691 shares.

The table below summarizes information about our purchases of common stock during the quarter ended March 31, 2019:

Period	Total Number of Shares Purchased		Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plan		Maximum Number of Shares That May Yet Be Purchased Under the Plan
Balance as of December 31, 2018		—	$	—		—		251,991
January 1, 2019 through January 31, 2019		61,000		9.50		61,000		190,991
February 1, 2019 through February 28, 2019		—		—		—		190,991
March 1, 2019 through March 31, 2019		16,300		10.13		16,300		174,691
		77,300	$	9.63		77,300

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

Not Applicable.

ITEM 5. OTHER INFORMATION.

None. 

24

ITEM 6. EXHIBITS

Number	Exhibit Description			Filing	Filed
		Form	Exhibit	Date	Herewith
31.01	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				X
31.02	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				X
32.01	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*				X
32.02	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*				X
101.INS+	XBRL Instance				X
101.SCH+	XBRL Taxonomy Extension Schema				X
101.CAL+	XBRL Taxonomy Extension Calculation				X
101.DEF+	XBRL Taxonomy Extension Definition				X
101.LAB+	XBRL Taxonomy Extension Labels				X
101.PRE+	XBRL Taxonomy Extension Presentation				X

* These certifications accompany this Quarterly Report on Form 10-Q. They are not deemed “filed” with the Securities and Exchange Commission and are not to be incorporated by reference in any filing of SWK Holdings Corporation under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any filings.

+ XBRL information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections. 

25

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on May 15, 2019.

SWK Holdings Corporation
By:	/s/ Winston L. Black
	Winston L. Black
	Chief Executive Officer
	(Principal Executive Officer)
By:	/s/ Charles M. Jacobson
	Charles M. Jacobson
	Chief Financial Officer
	(Principal Financial Officer)

26